Stephen Brady

Director at Tempest Therapeutics

Capital raised by Tempest Therapeutics

$6.1M+$4.1M latest round

2 Form D filings · first filed Mar 2026 · Brisbane, CA

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 3
FOUNDED: —
30D INTEREST: —

Career

1 company on file

Tempest TherapeuticsBiotech · Brisbane, CAsince Mar 2026

Director

Listed on Tempest Therapeutics's Form D filings

Company filings

via EDGAR · Form D for Tempest Therapeutics2

DateCompanyFormAmountRole on filing

May 29, 2026Tempest TherapeuticsForm D+$4.1M—

Form DMay 29, 2026 · Tempest Therapeutics+$4.1Mnot a signer

Mar 20, 2026Tempest TherapeuticsForm D+$2.0M—

Form DMar 20, 2026 · Tempest Therapeutics+$2.0Mnot a signer

Overview

Last filing May 29, 2026

Stephen Brady is on file as Director at Tempest Therapeutics in Brisbane, CA. Tempest Therapeutics has 2 Form D filings on record, $6.1M raised in total.

Teammates

Tempest Therapeutics · 2

Matthew AngelPresident and CEOSigner William RicheyDirector

Products

Tempest Therapeutics · 1

TPST-4003Clinical-stage cell therapy candidate

The lead in vivo CAR-T candidate, pairing Tempest's CD7-targeted mRNA lipid nanoparticle (CD7-tLNP) delivery platform with a dual-targeting CD19/BCMA chimeric antigen receptor.